Here are the 10-K annual reports from ProMIS Neurosciences Inc. (PMN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMN filings page.
ProMIS Neurosciences Inc. files its annual report describing a broad pipeline of antibody and vaccine candidates for neurodegenerative and misfolded protein diseases. Its lead program, PMN310 for Alzheimer’s disease, targets toxic amyloid-beta oligomers without binding monomers or plaque.
The company has completed enrollment of 144 patients in its Phase 1b PRECISE-AD trial across 21 U.S. sites, dosing monthly at 5, 10 or 20 mg/kg or placebo over 12 months. PMN310 has shown a generally favorable safety profile to date and received FDA Fast Track designation.
Beyond Alzheimer’s, ProMIS highlights preclinical programs for TDP-43 in ALS (PMN267), alpha-synuclein in synucleinopathies (PMN442), additional ALS targets such as RACK1 and SOD1, and vaccine efforts against amyloid-beta, alpha-synuclein and TDP-43. The report also outlines a layered intellectual property strategy built on licensed University of British Columbia algorithms, disease-specific epitopes, and antibody composition-of-matter patents.